Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

DRCR.Net Aflibercept vs. Bevacizumab + Uppskjuten aflibercept för behandling av CI-DME (DRCR AC)

9 september 2026 uppdaterad av: Jaeb Center for Health Research

Randomiserad prövning av intravitröst aflibercept kontra intravitröst bevacizumab + uppskjuten aflibercept för behandling av centralinvolverat diabetiskt makulaödem

Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss.

Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

270

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Campbell, California, Förenta staterna, 95008
        • Retinal Diagnostic Center
      • Glendale, California, Förenta staterna, 91203
        • Macula & Retina Institute
      • Loma Linda, California, Förenta staterna, 92354
        • Loma Linda University Health Care, Department of Ophthalmology
      • Oakland, California, Förenta staterna, 94609-3028
        • East Bay Retina Consultants, Inc
    • Florida
      • Fort Myers, Florida, Förenta staterna, 33912
        • National Ophthalmic Research Institute
      • Jacksonville, Florida, Förenta staterna, 32216
        • Florida Retina Institute-Jacksonville
      • Lakeland, Florida, Förenta staterna, 33805
        • Florida Retina Consultants
      • Miami, Florida, Förenta staterna, 33126
        • Retina Macula Specialists of Miami
      • Orlando, Florida, Förenta staterna, 32806
        • Florida Retina Institute
      • Orlando, Florida, Förenta staterna, 32806
        • Central Florida Retina
      • Pinellas Park, Florida, Förenta staterna, 33782
        • Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
      • Plantation, Florida, Förenta staterna, 33324
        • Fort Lauderdale Eye Institute
      • Sarasota, Florida, Förenta staterna, 34239
        • Sarasota Retina Institute
      • Sarasota, Florida, Förenta staterna, 34233
        • Retina Associates of Sarasota
      • Tampa, Florida, Förenta staterna, 33609
        • Retina Associates of Florida, LLC
      • Wesley Chapel, Florida, Förenta staterna, 33544
        • Retina Specialists of Tampa
    • Georgia
      • Augusta, Georgia, Förenta staterna, 30909
        • Southeast Retina Center, P.C.
      • Sandy Springs, Georgia, Förenta staterna, 30328
        • Thomas Eye Group
    • Illinois
      • Oak Park, Illinois, Förenta staterna, 60304
        • Illinois Retina Associates, S.C.
      • Springfield, Illinois, Förenta staterna, 62703
        • Springfield Clinic, LLP
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46290
        • Raj K. Maturi, M.D., P.C.
      • New Albany, Indiana, Förenta staterna, 47150
        • John-Kenyon American Eye Institute
    • Kansas
      • Overland Park, Kansas, Förenta staterna, 66211
        • Mid-America Retina Consultants, P.A.
      • Shawnee Mission, Kansas, Förenta staterna, 66204
        • Retina Associates, P.A.
    • Kentucky
      • Paducah, Kentucky, Förenta staterna, 42001
        • Paducah Retinal Center
    • Louisiana
      • West Monroe, Louisiana, Förenta staterna, 71291
        • Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
    • Maryland
      • Hagerstown, Maryland, Förenta staterna, 21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Ayer, Massachusetts, Förenta staterna, 01432
        • Valley Eye Physicians and Surgeons
      • Boston, Massachusetts, Förenta staterna, 02215
        • Joslin Diabetes Center
    • Michigan
      • Grand Rapids, Michigan, Förenta staterna, 49546
        • Vitreo-Retinal Associates
      • Grand Rapids, Michigan, Förenta staterna, 49546
        • Retina Specialists of Michigan
    • Missouri
      • St Louis, Missouri, Förenta staterna, 63128
        • The Retina Institute
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87109
        • Eye Associates of New Mexico
    • New York
      • New York, New York, Förenta staterna, 10021
        • MaculaCare
      • Rochester, New York, Förenta staterna, 14620
        • Retina Associates of Western New York
    • North Carolina
      • Asheville, North Carolina, Förenta staterna, 28803
        • Western Carolina Clinical Research, LLC
      • Charlotte, North Carolina, Förenta staterna, 28210
        • Charlotte Eye, Ear, Nose and Throat Assoc., PA
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • University Hospitals Cleveland Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • Dean A. McGee Eye Institute
    • Oregon
      • Portland, Oregon, Förenta staterna, 97221
        • Retina Northwest, PC
      • Springfield, Oregon, Förenta staterna, 97477
        • Cascade Medical Research Institute, LLC
    • Pennsylvania
      • Monroeville, Pennsylvania, Förenta staterna, 15146
        • Retina Vitreous Consultants
      • Philadelphia, Pennsylvania, Förenta staterna, 19107-5109
        • Retinavitreous Associates, dba; Mid Atlantic Retina
    • Tennessee
      • Knoxville, Tennessee, Förenta staterna, 37909
        • Southeastern Retina Associates, P.C.
    • Texas
      • Austin, Texas, Förenta staterna, 78705
        • Austin Retina Associates
      • Austin, Texas, Förenta staterna, 78705
        • Retina Research Center
      • Grapevine, Texas, Förenta staterna, 76051
        • Retina Center of Texas
      • Houston, Texas, Förenta staterna, 77030
        • Retina Consultants of Houston, PA
      • Houston, Texas, Förenta staterna, 77030
        • Baylor Eye Physicians and Surgeons
      • Lubbock, Texas, Förenta staterna, 79424
        • Texas Retina Associates
      • McAllen, Texas, Förenta staterna, 78503
        • Valley Retina Institute
      • San Antonio, Texas, Förenta staterna, 78240
        • Retinal Consultants of San Antonio
    • Washington
      • Spokane, Washington, Förenta staterna, 99204
        • Spokane Eye Clinic
    • Wisconsin
      • Milwaukee, Wisconsin, Förenta staterna, 53226
        • Medical College of Wisconsin

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Participant-level Criteria Inclusion

To be eligible, the following inclusion criteria must be met:

  1. Age ≥ 18 years • Individuals <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable.

  2. Diagnosis of diabetes mellitus (type 1 or type 2)

    • Any one of the following will be considered to be sufficient evidence that diabetes is present:

    Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by American Diabetes Association and/or World Health Organization criteria

  3. At least one eye meets the study eye criteria listed.

  4. Able and willing to provide informed consent.

    Exclusion

    An individual is not eligible if any of the following exclusion criteria are present:

  5. Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.

  6. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).

    • Individuals in poor glycemic control who, within the last four months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next four months should not be enrolled.
  7. Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied at the time of study entry.

    • Note: study participants cannot receive another investigational drug while participating in the study.

  8. Known allergy to any component of the study drug or any drug used in the injection prep (including povidone iodine prep).

  9. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).

    • If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.

  10. Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.

    • These drugs cannot be used during the study.

  11. For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 24 months.

    • Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.

  12. Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next two years.

Study Eye Criteria The study participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below.

Study participants can have two study eyes only if both eyes are eligible at the time of randomization. For study participants with two eligible eyes, the logistical complexities of the protocol must be considered for each individual prior to randomizing both eyes.

The eligibility criteria for a study eye are as follows:

Inclusion

  1. Best corrected Electronic-Early Treatment Diabetic Retinopathy Study visual acuity letter score < 69 (i.e., 20/50 or worse) and ≥ 24 (i.e., 20/320 or better) within eight days of randomization.

  2. On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.

  3. Diabetic macular edema present on optical coherence tomography (OCT) within eight days of randomization

    • Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men
    • Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men
    • Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality
  4. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus photographs.

    Exclusions

    The following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):

  5. Macular edema is considered to be due to a cause other than diabetic macular edema.

    • An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema.

  6. An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).

  7. An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).

  8. Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).

  9. History of an anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in the past 12 months or history of any other treatment for DME at any time in the past four months (such as focal/grid macular photocoagulation, intravitreous or peribulbar corticosteroids).

    • Enrollment will be limited to a maximum of 25% of the planned sample size with any history of anti-VEGF treatment for DME. Once this number of eyes has been enrolled, any history of anti-VEGF treatment for DME will be an exclusion criterion.

  10. History of pan-retinal photocoagulation within four months prior to randomization or anticipated need for pan-retinal photocoagulation in the six months following randomization.

  11. History of anti-VEGF treatment for a disease other than DME in the past 12 months.

  12. History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior four months or anticipated within the next six months following randomization.

  13. History of YAG capsulotomy performed within two months prior to randomization.

  14. Aphakia.

  15. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.

  16. Evidence of uncontrolled glaucoma. • Intraocular pressure must be <30, with no more than one topical glaucoma medication, and no documented glaucomatous field loss for the eye to be eligible

Note, combination therapies are considered more than one medication

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Aflibercept Group

2.0 mg intravitreous aflibercept

Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.

Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.

Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using sterile technique

Andra namn:
  • Eylea
Experimentell: Bevacizumab + Deferred Aflibercept Group

1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria

Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.

Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.

Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using sterile technique

Andra namn:
  • Eylea

Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.

Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.

Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using a sterile technique.

Andra namn:
  • Avastin

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean Change in Visual Acuity
Tidsram: 2 years

Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up.

2 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Antal besök
Tidsram: 2 år
2 år
Antal ögon i den Bevacizumab-första gruppen som uppfyller byteskriterierna
Tidsram: Baslinje till 12 veckor
Baslinje till 12 veckor
Antal ögon i den Bevacizumab-första gruppen som uppfyller byteskriterierna
Tidsram: Baslinje till 24 veckor
Baslinje till 24 veckor
Antal ögon i den Bevacizumab-första gruppen som uppfyller byteskriterierna
Tidsram: Baslinje till 52 veckor
Baslinje till 52 veckor
Antal ögon i den Bevacizumab-första gruppen som uppfyller byteskriterierna
Tidsram: Baslinje till 104 veckor
Baslinje till 104 veckor
Change in Visual Acuity From Baseline
Tidsram: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Increase in E-ETDRS Visual Acuity Letter Score
Tidsram: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Decrease in E-ETDRS Visual Acuity Letter Score
Tidsram: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Visual Acuity
Tidsram: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
Tidsram: 2 years

Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.

2 years
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema
Tidsram: 2 years

Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss).

2 years
Number of Injections
Tidsram: 2 years

All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group.

2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 december 2017

Primärt slutförande (Faktisk)

22 december 2021

Avslutad studie (Faktisk)

22 december 2021

Studieregistreringsdatum

Först inskickad

23 oktober 2017

Först inskickad som uppfyllde QC-kriterierna

23 oktober 2017

Första postat (Faktisk)

25 oktober 2017

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

1 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera